The BX Energy Catalyst

BX Technical: Presented by D. Smith, PH.D., Director of Delta (For Bio-Chemists only)

Photocatalytic Oxidation of the Stealth Bacterium

Mode of Action:

The bactericidal effects of the BX Antitoxin are herein set forth.  The highly diluted compound elicits efficient fluorescent absorption of bacterial toxins through accelerated photocatalytic oxidation, demonstrating high antibacterial action against the stealth bacterium, the causative agent of malignancy.  .
When the Antitoxin comes in contact with the stealth bacterium it releases free radicals such as 03, and H202.  The significance and novelty of the bio-molecule is its ability to postpone the release of the potent oxidizers until they begin to interact in a manner specific to the intensity of the valence vibrational frequencies of the amine group chemistry of the bacterium.

Because the photocatalytic bactericidal activity of the Antitoxin is so high, we are able to rely on low concentrations of the bio-molecule within the human body.  In this sense the molecule could be viewed as homeopathic.  However, it’s the ability of the substance to initiate oxidation dispersal within the bacterium that allows the reaction to geometrically progress and spread from cell to cell, which could be equated to the relationship between a matchstick and a forest fire.     

Simply put, the BX Antitoxin absorbs the vital energy of the stealth bacterium in a manner that yields tremendous antibacterial action without bio-toxicity.

As a result of the death of the stealth bacteria, the tumor cells also start dying via the now released apoptotic or necrotic pathways. The Herxheimer reaction from the release of die-off materials from the bacteria and the cancer cells provide an indication of the product in action.

The BX Antitoxin is a highly diluted, non-toxic derivative of specific substrates capable of retaining electrostatic energy.

Carrier agents for the BX Energy charge, such as Robinia, are manufactured in India in accordance with the United States Pharmacopoeia (USP) and the Homeopathic Pharmacopoeia of the United States (HPUS).

The BX is regulated in several countries as a homeopathic medicine; therefore, labels pertaining to distribution in specific countries may omit certain product designations contained on the BX Protocol website such as; BX, BX Energy Catalyst, BX Antitoxin, etc., in order to maintain labeling standards within that specific jurisdiction. Some countries may also require a prescription from a duly licensed practitioner. Delta Healthcare practitioners must evaluate each member to determine applicability of product based on the members needs and evaluate the need for a prescription based on jurisdictional considerations. Delta must verify qualifications of potential members before granting access to this product. UPC/NDC Numbers are available upon request and jurisdictional requirements for disclosure.

The BX Antitoxin catalyzes the transfer dehydrogenation of the bacterial amines involved. Dehydrogenation occurs across C-N bonds and forms a non-toxic intermediate which serve the role of an electron acceptor.  The selectivity of dehydrogenation of bacterial amines is governed by multidimensional steric parameters controlled during synthesis of the molecule.    

The BX Antitoxin is charting a new course in understanding the physiology of the stealth bacterium.   

Note: For the purposes of this site, the terms "Antitoxin" and "Energy Catalyst" are synonymous.  The use of one or the other is dependent on jurisdiction and applicable labeling laws and other regulatory considerations. Patent Pending.